JP2020519308A5 - - Google Patents

Download PDF

Info

Publication number
JP2020519308A5
JP2020519308A5 JP2020512919A JP2020512919A JP2020519308A5 JP 2020519308 A5 JP2020519308 A5 JP 2020519308A5 JP 2020512919 A JP2020512919 A JP 2020512919A JP 2020512919 A JP2020512919 A JP 2020512919A JP 2020519308 A5 JP2020519308 A5 JP 2020519308A5
Authority
JP
Japan
Prior art keywords
antigen
antibody
binding fragment
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020512919A
Other languages
English (en)
Japanese (ja)
Other versions
JP7118135B2 (ja
JP2020519308A (ja
Filing date
Publication date
Priority claimed from GBGB1707561.5A external-priority patent/GB201707561D0/en
Application filed filed Critical
Publication of JP2020519308A publication Critical patent/JP2020519308A/ja
Publication of JP2020519308A5 publication Critical patent/JP2020519308A5/ja
Priority to JP2022122483A priority Critical patent/JP2022169549A/ja
Application granted granted Critical
Publication of JP7118135B2 publication Critical patent/JP7118135B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020512919A 2017-05-11 2018-05-11 GARP-TGF-β抗体 Active JP7118135B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022122483A JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1707561.5A GB201707561D0 (en) 2017-05-11 2017-05-11 GARP-TGF-beta antibodies
GB1707561.5 2017-05-11
PCT/EP2018/062251 WO2018206790A1 (en) 2017-05-11 2018-05-11 GARP-TGF-β ANTIBODIES

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022122483A Division JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Publications (3)

Publication Number Publication Date
JP2020519308A JP2020519308A (ja) 2020-07-02
JP2020519308A5 true JP2020519308A5 (enExample) 2022-01-25
JP7118135B2 JP7118135B2 (ja) 2022-08-15

Family

ID=59201573

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2020512919A Active JP7118135B2 (ja) 2017-05-11 2018-05-11 GARP-TGF-β抗体
JP2022122483A Withdrawn JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022122483A Withdrawn JP2022169549A (ja) 2017-05-11 2022-08-01 GARP-TGF-β抗体

Country Status (35)

Country Link
US (4) US10479829B2 (enExample)
EP (3) EP4086286A1 (enExample)
JP (2) JP7118135B2 (enExample)
KR (2) KR102664663B1 (enExample)
CN (1) CN110945027B (enExample)
AU (2) AU2018265241B2 (enExample)
BR (1) BR112019023735A8 (enExample)
CA (1) CA3061841C (enExample)
CL (1) CL2019003211A1 (enExample)
CO (1) CO2019013669A2 (enExample)
CR (1) CR20190561A (enExample)
CY (1) CY1125674T1 (enExample)
DK (1) DK3606961T3 (enExample)
DO (1) DOP2019000285A (enExample)
EC (1) ECSP19087742A (enExample)
ES (1) ES2921015T3 (enExample)
GB (1) GB201707561D0 (enExample)
HR (1) HRP20220787T1 (enExample)
HU (1) HUE059237T2 (enExample)
IL (2) IL270236B2 (enExample)
LT (1) LT3606961T (enExample)
MX (1) MX385670B (enExample)
MY (1) MY199335A (enExample)
NZ (1) NZ758647A (enExample)
PE (1) PE20200618A1 (enExample)
PH (1) PH12019502526A1 (enExample)
PL (1) PL3606961T3 (enExample)
PT (1) PT3606961T (enExample)
RS (1) RS63361B1 (enExample)
RU (1) RU2767784C2 (enExample)
SG (1) SG10201914130VA (enExample)
SI (1) SI3606961T1 (enExample)
SM (1) SMT202200284T1 (enExample)
UA (1) UA125534C2 (enExample)
WO (1) WO2018206790A1 (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002362197A1 (en) * 2001-12-28 2003-07-24 Chugai Seiyaku Kabushiki Kaisha Method of stabilizing protein
WO2017173091A1 (en) * 2016-03-30 2017-10-05 Musc Foundation For Research Development Methods for treatment and diagnosis of cancer by targeting glycoprotein a repetitions predominant (garp) and for providing effective immunotherapy alone or in combination
CN120022360A (zh) 2019-08-28 2025-05-23 中外制药株式会社 跨物种抗潜伏TGF-β1抗体和使用方法
CN114630679A (zh) 2019-10-25 2022-06-14 第一三共株式会社 抗garp抗体和免疫调节剂的组合
CA3167427A1 (en) * 2020-01-11 2021-07-15 Scholar Rock, Inc. Tgfb inhibitors and use thereof
JP7842690B2 (ja) 2020-02-19 2026-04-08 ナミ セラピューティクス, インコーポレイテッド がんの処置において有用なTFGβアンタゴニストプロドラッグを含有する製剤化および/または共製剤化リポソーム組成物ならびにその方法
US20230192867A1 (en) * 2020-05-15 2023-06-22 Bristol-Myers Squibb Company Antibodies to garp
CN117295767A (zh) * 2020-11-11 2023-12-26 Versapeutics公司 针对wnt受体ryk的抗体变体
CN116723861A (zh) * 2020-12-02 2023-09-08 上海复宏汉霖生物技术股份有限公司 抗GARP/TGFβ抗体及使用方法
KR20230169936A (ko) * 2021-01-18 2023-12-18 상하이 제민케어 파마슈티칼 컴퍼니 리미티드 Garp 단백질 항체 및 이의 적용
US20250282857A1 (en) * 2021-03-26 2025-09-11 Scholar Rock, Inc. Tgf-beta inhibitors and use thereof
US20240425571A1 (en) * 2021-10-11 2024-12-26 Ohio State Innovation Foundation Glycoprotein a repetitions predominant (garp)-binding antibodies and uses thereof
PY2336430A (es) 2022-05-18 2023-11-27 Vestaron Corp Variantes de péptidos pesticidas actx
US20260029402A1 (en) 2022-07-22 2026-01-29 Institut National de la Santé et de la Recherche Médicale Garp as a biomarker and biotarget in t-cell malignancies
US20240042020A1 (en) 2022-07-29 2024-02-08 Abbvie Biotherapeutics Inc. Anti-garp-tgf-beta1/pd-1 combination therapy
CN120418286A (zh) 2023-01-09 2025-08-01 北京拓界生物医药科技有限公司 TGFβ1结合分子、GARP-TGFβ1结合分子及其医药用途
WO2024164807A1 (zh) * 2023-02-06 2024-08-15 贝达药业股份有限公司 多特异性抗体及其应用

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5892019A (en) 1987-07-15 1999-04-06 The United States Of America, As Represented By The Department Of Health And Human Services Production of a single-gene-encoded immunoglobulin
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
DE69233528T2 (de) 1991-11-25 2006-03-16 Enzon, Inc. Verfahren zur Herstellung von multivalenten antigenbindenden Proteinen
NZ298145A (en) 1994-12-29 1998-08-26 Yamanouchi Pharma Co Ltd Monoclonal antibodies having inhibitory effect on type ii phospholipase a2, proteins forming part thereof, cells producing them, dna encoding them, recombinant vector comprising the dna and medicament
US7709610B2 (en) 2003-05-08 2010-05-04 Facet Biotech Corporation Therapeutic use of anti-CS1 antibodies
ES2304069B1 (es) * 2003-08-22 2009-08-12 Proyecto De Biomedicina Cima, S.L. Peptidos con capacidad de unirse al factor transformante de crecimiento beta 1 (tgf-b1).
US20070048785A1 (en) 2004-06-09 2007-03-01 Lin Laura L Anti-IL-13 antibodies and complexes
WO2006103639A2 (en) 2005-03-31 2006-10-05 Case Western Reserve University Methods and reagents for identifying/isolating t regulatory (treg) cells and for treating individuals
WO2007113301A1 (en) 2006-04-03 2007-10-11 Medizinische Hochschule Hannover Pharmaceuticals for influencing the reaction of the human immune system
WO2009073163A1 (en) 2007-12-03 2009-06-11 American Type Culture Collection (Atcc) Avian influenza antibodies, compositions, and methods thereof
GB2461546B (en) 2008-07-02 2010-07-07 Argen X Bv Antigen binding polypeptides
WO2010022341A1 (en) 2008-08-21 2010-02-25 The United State Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of enriching and using regulatory t cells
KR101492052B1 (ko) 2012-06-26 2015-02-10 (주)대창솔루션 액화가스 운반용 탱크
AU2013310924B2 (en) 2012-08-31 2017-08-03 Argenx Bvba Method for producing antibody molecules having inter-species, intra-target cross-reactivity
HRP20201914T1 (hr) 2013-05-06 2021-01-22 Scholar Rock, Inc. Sastavi i postupci za modulaciju faktora rasta
AU2014298373B2 (en) * 2013-08-01 2019-12-05 Ludwig Institute For Cancer Research Ltd Anti-GARP protein and uses thereof
EP2832747A1 (en) 2013-08-01 2015-02-04 Université Catholique de Louvain Anti-GARP protein and uses thereof
WO2016125017A1 (en) * 2015-02-03 2016-08-11 Universite Catholique De Louvain Anti-garp protein and uses thereof
CN110922481A (zh) * 2015-09-24 2020-03-27 第一三共株式会社 抗garp抗体
EP3484499A4 (en) 2016-07-14 2020-05-13 Scholar Rock, Inc. TGFB ANTIBODIES, METHODS AND USE

Similar Documents

Publication Publication Date Title
US20230242651A1 (en) Stable antibody variable domain framework combinations
JP2025016349A5 (enExample)
JP2022031635A5 (enExample)
JP2020079252A5 (enExample)
RU2019140602A (ru) АНТИ-GARP-TGF-β-АНТИТЕЛА
JP2018521638A5 (enExample)
JP2019201643A5 (enExample)
FI3322727T3 (fi) Humanisoituja tai kimeerisiä CD3-vasta-aineita
JP2018183173A5 (enExample)
JP2021524267A5 (enExample)
EP3645741A2 (en) Anti-4-1bb antibodies and methods of making and using thereof
JP2018522541A5 (enExample)
HRP20200390T1 (hr) Monoklonska antitijela protiv humanog antigena starenja b stanica (bcma)
JP2018526981A5 (enExample)
JP2017169559A5 (enExample)
JP2020514277A5 (enExample)
JP2022529154A5 (enExample)
JP2021534797A5 (enExample)
RU2014153440A (ru) Антитела против cd26 и их применение
JP2010516229A5 (enExample)
RU2019111862A (ru) Новые антитела против фактора xi и их применения
JP2021511387A5 (enExample)
FI4200018T3 (fi) Anti-par-2-vasta-aineet ja niiden käyttömenetelmät
JP2018529672A5 (enExample)
JP2022501065A5 (enExample)